Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Cash & Equivalents (2024 - 2026)

Maze Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $198.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 32.48% to $198.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $198.8 million, a 32.48% decrease, with the full-year FY2025 number at $189.2 million, down 3.84% from a year prior.
  • Cash & Equivalents hit $198.8 million in Q1 2026 for Maze Therapeutics, up from $189.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for MAZE hit a ceiling of $316.8 million in Q3 2025 and a floor of $30.0 million in Q1 2024.
  • Historically, Cash & Equivalents has averaged $201.7 million across 3 years, with a median of $196.8 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: surged 880.49% in 2025 and later crashed 32.48% in 2026.
  • Tracing MAZE's Cash & Equivalents over 3 years: stood at $196.8 million in 2024, then fell by 3.84% to $189.2 million in 2025, then grew by 5.03% to $198.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for MAZE at $198.8 million in Q1 2026, $189.2 million in Q4 2025, and $316.8 million in Q3 2025.